Adenosine Nucleotides Acting at the Human P2Y1 Receptor Stimulate Mitogen-activated Protein Kinases and Induce Apoptosis*

Lynda A. SellersDagger §, Joseph SimonDagger , Tina S. LundahlDagger , Diane J. Cousens, Patrick P. A. HumphreyDagger , and Eric A. BarnardDagger

From the Dagger  Glaxo Institute of Applied Pharmacology, Department of Pharmacology, University of Cambridge, Cambridge CB2 1QJ and the  7TM Receptor Systems Unit, Molecular Pharmacology Department, Glaxo Wellcome Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire 2G1 2NY, United Kingdom

Received for publication, July 25, 2000, and in revised form, January 17, 2001


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

For the widely distributed P2Y receptors for nucleotides, the transductional and functional responses downstream of their coupling to G proteins are poorly characterized. Here we describe apoptotic induction and the associated differential stimulation of mitogen-activated protein (MAP) kinase family members by the human P2Y1 receptor. The potent P2Y1 receptor agonist, 2-methylthio-ADP (2-MeSADP), stimulated the extracellular-signal regulated kinases (ERK1/2) (EC50 ~5 nM) as well as several, but not all isoforms detected, of the stress-activated protein kinase (SAPK) family. Phospho-isoforms of p38 were unaffected. The induced kinase activity was blocked by the P2Y1 receptor-selective antagonist, adenosine-2'-phosphate-5'-phosphate, but unaffected by pertussis toxin. In addition, the endogenous ligand ADP, and significantly also 2-MeSATP, induced concentration-dependent phosphorylation changes in the same MAP kinase family members. The sustained activation of ERK1/2 was associated with Elk-1 phosphorylation that was abolished by the MEK1 inhibitor, PD 98059. However, the concomitant transient activation of the SAPKs was not sufficient to induce c-Jun or ATF-2 phosphorylation. The transient phase of the ERK activity was partially inhibited either by the phosphatidylinositol 3-kinase inhibitor, LY 294002, or the PKC inhibitor, Gö 6976. In addition, the Src inhibitor, PP1, or expression of dominant negative Ras also attenuated the transient phase of ERK phosphorylation. In contrast, inhibition of Ras or Src had no effect on the sustained ERK activity, which was critically dependent on phosphatidylinositol 3-kinase. The transient SAPK activity was suppressed by expression of a dominant negative form of MKK4. Furthermore, this kinase-deficient mutant inhibited 2-MeSADP-induced caspase-3 stimulation and the associated decrease in cell number. In conclusion, adenosine di- and triphosphate stimulation of the human P2Y1 receptor can transiently activate the Ras-ERK cascade via the cooperative effects of phosphatidylinositol 3-kinase, Src and PKC. The sustained ERK stimulation, via a Ras-insensitive pathway, culminates in Elk-1 activation without inducing a proliferation effect. The transient SAPK activity did not evoke transcription factor phosphorylation but was required for the P2Y1 receptor-mediated apoptotic function.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Extracellular nucleotides can interact with cell surface P2 receptors both in the central nervous system and in peripheral tissues to produce a broad range of physiological effects. The P2 family is divided into two main types as follows: the P2X receptors are ligand-gated ion channels, and the P2Y receptors are G protein-coupled (1, 2). Part of the present study describes the signaling pathways of the P2Y1 receptor, the first member of the P2Y family to be identified (3). The P2Y1 receptor is widely distributed and has been described in mammalian heart, vascular, liver, kidney, prostate, gastrointestinal, pulmonary, connective, and immune tissues (4, 5). It has also been identified in skeletal muscle and appears to be the most abundant P2 receptor in the nervous system (5-7). ADP and more potently 2-methylthio-ADP (2-MeSADP)1 are agonists at the P2Y1 receptor, but its activation by ATP and 2-MeSATP has been controversial. Due to the ready conversion of triphosphates by ectonucleotidases to the aforementioned agonistic diphosphates, some earlier findings are in doubt. Thus, it is important to maintain totally the triphosphate integrity by a constant regenerating system (8, 9), which has been included in the experimental design of the present study. With such precautions in place, the recombinant P2Y1 receptor can be activated by ATP and 2-MeSATP (10, 11), whereas others (9) have found these ligands to be antagonists in other cell systems. This difference has been proposed to depend critically on the degree of P2Y1 receptor reserve (10, 11).

The second messengers generated by the P2Y1 receptor are due to the activation of phospholipase Cbeta leading to the formation of diacylglycerol as well as inositol trisphosphate (12, 13) and mobilization of intracellular Ca2+ (9, 10), suggesting that the subsequent activation of protein kinase C (PKC) is likely. These responses are insensitive to pertussis toxin, and the G protein involved has been identified as G11 in the case of the turkey erythrocyte (14), but Gq can also act at the P2Y1 receptor in some systems including the human platelet (15). Furthermore, a primary signaling action of the P2Y1 receptor in neurons is the closing of an N-type Ca2+ channel (11), and in platelets there is some suggestion that the P2Y1 receptor is coupled to the RhoA-ROCK pathway (16). It is known that activation of PKC isoforms by G protein-coupled receptors can stimulate the extracellular signal-regulated kinases (ERKs), which are members of the mitogen-activated protein (MAP) kinase family (17). For the P2Y receptors, activation of the ERK cascade has been shown in several cell types including astrocytes (18, 19), endothelial cells (20, 21), vascular smooth muscle cells (22), and renal mesangial cells (23). However, since the cells studied co-express several types of P2Y receptors or have an unknown complement of purinoceptors, the downstream events observed have not identified those associated with a single, molecularly defined, P2Y receptor.

The MAP kinases are proline-directed serine/threonine kinases that have been classified into at least four subfamilies as follows: ERKs, stress-activated protein kinases (SAPKs), p38 kinases, and BMK1/ERK5 (17). Whereas ERKs are implicated in cell growth as well as differentiation, SAPKs and p38 appear to play a role in regulating the cell death machinery (24). Whereas the pathway linking cell surface receptors to ERKs has been partially elucidated, the mechanism of activation of p38 and SAPKs is poorly understood. This is particularly so for members of the G protein-coupled receptor family, which have only recently been shown to utilize these alternative MAP kinase cascades for transduction purposes. Activation of p38 and SAPKs has been demonstrated following stimulation of the Gq/G11-coupled m1 and Gi-coupled m2 muscarinic acetylcholine receptors (25, 26). More recent studies have also shown p38 activation in rat glomerular mesangial cells following stimulation with UTP and ATP, possibly mediated through the P2Y2 receptor (27). In addition, stimulation of P2Y2 receptors in C6 glioma cells (28) and/or P2Y4 receptors in rat glomerular mesangial cells can induce proliferation (29). At present apoptosis initiated by nucleotides is known only for a P2X receptor, being a prominent consequence of P2X7 receptor activation in human macrophages and leukocytes as well as in mesangial, dendritic, and microglial cells (30, 31). As with most examples of apoptosis, the P2X7 receptor-initiated cascade, which includes the coupling of the ion channel to the SAPK-signaling cascade (32), involves a defined sequence of phenotypic changes that culminate in death only several hours after the exposure to ATP.

The goal of this study was to examine the ability of the human recombinant P2Y1 receptor, heterologously expressed in human astrocytoma cells (1321N1, containing no endogenous P2Y receptors) to stimulate the MAP kinase transduction cascades. A specific antagonist of the P2Y1 receptor was applied to confirm the authenticity of the responses observed. In addition, the time course of the MAP kinase activity was also determined. There is much evidence to suggest that the duration of ERK activity is critically important for determining functional outcome (33, 34), and in every case examined thus far, only sustained ERK activation induces cytoplasmic nuclear migration (35, 36). Prolonged stimulation of ERK will therefore have very different consequences for gene expression compared with that of transient activation. Part of this study was thus to determine if the duration of the other MAP kinase cascades is similarly important for controlling transcriptional events. In addition, it was determined whether the P2Y1 receptor-mediated MAP kinase activities could be correlated with either a proliferative or an apoptotic functional response.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- The 1321N1 astrocytoma cell line heterologously expressing the human P2Y1 receptor (5) was a generous gift from Dr. S. P. Kunapuli (Temple University, Philadelphia). All tissue culturing media and reagents were purchased from Life Technologies, Inc., and plasticware was from Costar. Carbamylcholine chloride (carbachol), creatine phosphokinase, creatine phosphate, 2-MeSADP, 2-MeSATP, and adenosine-2'-phosphate-5'-phosphate (A2P5P) were purchased from Sigma. ADP and hexokinase were from Roche Molecular Biochemicals. Antibodies specific to ERK1 and ERK2 were obtained from Santa Cruz Biotechnology. Polyclonal antibodies specific for the dually phosphorylated and hence active forms of ERK1 and ERK2 (at Thr202 and Tyr204), alpha , beta , and delta  isoforms of p38 (at Thr180 and Tyr182), and SAPK family members (at Thr183 and Tyr185), together with antibodies to p38 and SAPKs with a specificity for the kinases independent of their phosphorylation state, were all obtained from New England Biolabs. Antibodies to the transcription factors c-Jun, Elk-1, and ATF-2 as well as those to the phosphorylated forms of these proteins were also supplied by New England Biolabs. The PKC inhibitors, Gö 6976 and Ro 32-1432, as well as Bordetella pertussis toxin, the MEK1 inhibitor, PD 98059, the Src inhibitor, PP1, and the phosphatidylinositol 3-kinase (PI 3-K) inhibitor, LY 294002, were all from Calbiochem. Antibodies to the G protein alpha  subunits were from Santa Cruz Biotechnology. An anti-MKK4 (SEK1) antibody was obtained from New England Biolabs. Antibodies specific for Ras (L2 region) and human Ha-RAS cDNA (dominant negative S17N mutant) in pUSEamp, together with the empty vector, were supplied by Upstate Biotechnology, Inc. Staurosporin, FITC-conjugated annexin V, and a caspase-3 substrate that is cleaved to release a colorimetric product were all from CLONTECH.

Enzymatic Conversion of Tri- or Diphosphate Contamination-- ATP and ADP analogues are metabolically unstable and can be degraded by various ectonucleotidases present on cells. In addition, commercially available nucleotides often contain other nucleotides as by-products. Therefore, enzymatic systems that regenerate degraded nucleotides were routinely used in all experimental procedures carried out in this study. To eliminate the diphosphate contamination of 2-MeSATP, the creatine phosphokinase-regenerating system was used according to a method described previously (9). Thus, 1 mM stock solutions of 2-MeSATP were treated with 20 units ml-1 creatine phosphokinase in the presence of 10 mM creatine phosphate for 90 min at 37 °C. In order to ensure the purity of ADP and 2-MeSADP, 1 mM stock solutions were treated with 10 units ml-1 hexokinase, 0.1 M glucose for 60 min at room temperature to convert the triphosphate contamination to diphosphates (37). The appropriate enzymes (with their substrates) were also included (at 1 unit ml-1) in the culture medium during all experiments.

Tissue Culture-- Human astrocytoma cells (1321N1) stably expressing the human recombinant P2Y1 receptor were cultured in Dulbecco's modified Eagle's medium/Nutrient Mix F-12 medium (1:1) containing Glutamax I, pyridoxine hydrochloride, 10% fetal bovine serum, and 600 µg ml-1 geneticin sulfate (G-418). The cells were maintained at 37 °C in a humidified atmosphere (95% air, 5% CO2) and passaged by trypsinization every 4-5 days. For MAP kinase activity experiments, cells were plated in 6-well plates at an original seeding density of 200,000 cells per well and cultured to 80% confluence.

Activation of MAP Kinases by Nucleotides-- Cells were serum-starved for 4 h before incubation with incomplete media containing various drug treatments for the appropriate times at 37 °C. Reactions were terminated by removing the media and adding 150 µl of 3× concentrated Laemmli sample buffer. Following solubilization, the well contents were transferred to Eppendorf vials, and the wells were rinsed with 100 µl of distilled H2O. Equivalent amounts of protein were electrophoretically resolved on 10% polyacrylamide gels. Following electrophoretic transfer onto nitrocellulose (0.22 µm) using a semi-dry blotter, the membrane was washed briefly in Tris-buffered saline (TBS) and saturated overnight in TBS supplemented with 0.1% Tween 20 and 5% dried milk. For detection of the phosphorylated forms of the kinases, the nitrocellulose membrane was incubated with a 1:800 dilution of the anti-phosphospecific antibodies. Primary incubations were for 1 h at 22 °C in TBS containing 0.1% Tween 20 (TBST) followed by washing five times for 10 min each in TBST. Membranes were incubated for 1 h at 22 °C with a 1:3,000 dilution of the appropriate horseradish peroxidase-conjugated secondary antibody in TBST containing 5% dried milk. Excess antibody was removed by washing as above, and immunocomplexes were visualized using enhanced chemiluminescence detection, according to the manufacturer's instructions (Amersham Pharmacia Biotech). In order to substantiate the consistency of protein content between treatment groups, the membranes were re-probed with phosphorylation state independent antibodies to ERK1 and ERK2 (1:1,000 dilution) or SAPK/p38 (1:500 dilution) for 1 h at 22 °C and processed as above. The Western blots shown are representative of three separate experiments, and each panel is taken from a single immunoblot.

Phosphorylation of Transcription Factors-- Samples obtained from the 2-MeSADP time course experiments were separated on 10% polyacrylamide gels and transferred onto nitrocellulose membrane as described above. The membrane was incubated with primary antibodies specific to the phosphorylated forms of the transcription factors ATF-2, Elk-1, and c-Jun (1:400 dilution) for 1 h at 22 °C. The transcriptional activity of c-Jun is regulated by phosphorylation at Ser63 and Ser73 by SAPKs. Antibodies specific to both these phosphorylation sites were used. Elk-1 is phosphorylated by ERK1 and ERK2 at a cluster of Ser/Thr motifs at its COOH terminus, and phosphorylation of Ser383 (to which the antibody was raised) has been shown to be critical for transcriptional activation. Activation of ATF-2 requires phosphorylation of Thr69 and Thr71, and these sites are both substrates for the p38 kinase as well as for the SAPKs. The antibody used was raised to a synthetic phospho-Thr71 peptide. For detection of total protein, phospho-independent antibodies to the transcription factors were used at a 1:500 dilution. The Western blots shown are representative of three separate experiments, and each panel is taken from a single immunoblot.

Detection of the P2Y1 Receptor and G Protein Complement-- Whole cell extracts from 1321N1 human astrocytoma cells expressing the human P2Y1 receptor were separated on 10% polyacrylamide gels and transferred onto nitrocellulose. Membranes were incubated with serial dilutions of an antibody that specifically recognizes the COOH-terminal of the human P2Y1 receptor (peptide sequence CTLNILPEFKQNGDTSL) or with antibodies recognizing different G protein alpha  subunits (1:250 dilution). All primary incubations were for 1 h at 22 °C and immunoreactivity was detected as described above.

Immunocytochemistry-- Astrocytoma cells (1321N1) stably expressing the recombinant P2Y1 receptor were grown on poly-L-lysine (100 µM ml-1)-treated glass coverslips in 12-well plates until they reached ~70% confluence. The media were removed from the wells, and the coverslips were rinsed for 5 min (times three) with phosphate-buffered saline (PBS), fixed with 2% formaldehyde in PBS for 30 min, and washed as above. The cells were incubated for 30 min in 500 µl of blocking solution (PBS containing 3% goat serum, 1% bovine serum albumin, and 0.1% Triton X-100) followed by overnight incubation at 4 °C with the primary antibody recognizing the P2Y1 receptor (1:200 dilution in blocking solution). Control coverslips were incubated with blocking solution alone. After three washes for 5 min each in PBS, the cells were incubated with 500 µl of the secondary antibody conjugated to cyanine 3 (at 1:1,000 dilution, Sigma) in blocking solution for 1 h at 22 °C. After three washes for 5 min each in PBS, the coverslips were removed from the wells, dipped in distilled water, and dried before being mounted onto slides using an antifade agent (DAKO). The fluorescence was visualized using a Nikon Optiphot-2 microscope.

Expression Plasmids-- Dominant negative human MKK4 (K95R) was constructed as described previously (38), and the full-length cDNA was cloned into the mammalian expression vector, pCMV. Human Ha-RAS (S17N) cDNA was inserted as an EcoRI fragment into pUSEamp also under the control of the cytomegalovirus promoter. Transfections were performed using the LipofectAMINETM reagent according to the protocol suggested by the manufacturer (Life Technologies, Inc.). Briefly, astrocytoma cells (1321N1) stably expressing the recombinant P2Y1 receptor at 50% confluence were transfected in serum-free media with 2 µg of DNA following complex formation with LipofectAMINETM reagent. The DNA-containing media were removed following incubation for 3 h at 37 °C, and the cells were incubated with complete medium. Gene expression using immunoblot analysis as described above was determined immediately prior to drug additions, ~48 h post-transfection using a primary antibody concentration of 1:1,000.

Annexin V Binding-- In normal, non-apoptotic cells, phosphatidylserine is segregated to the inner leaflet of the plasma membrane. During early stages of apoptosis, this asymmetry collapses, and phosphatidylserine becomes exposed on the outer surface of cells (39). Annexin V is a protein that preferentially binds to phosphatidylserine in a Ca2+-dependent manner. Binding of annexin V in conjunction with propidium iodide exclusion to establish membrane integrity was used to identify apoptotic cells. Astrocytoma cells heterologously expressing the recombinant P2Y1 receptor were grown on poly-L-lysine (100 µM ml-1)-treated glass coverslips in 12-well plates until ~40% confluence was reached. The cells were serum-starved for 1 h before a 5-h incubation in the presence of various agents. The media were removed from the wells, and the coverslips were rinsed in ice-cold PBS. The coverslips were incubated for 15 min in the dark at 22 °C with 200 µl of binding buffer (150 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, 10 mM NaHEPES, pH 7.4) containing 0.5 µg ml-1 annexin V-FITC and 10 µg ml-1 propidium iodide. The coverslips were washed twice in binding buffer, dried, and mounted onto microscope slides as described above. Annexin V-FITC binding and propidium iodide incorporation were detected using either a Nikon Optiphot-2 microscope or a confocal laser scanning microscope (Zeiss LSM 510) with FITC excitation at 488 nm, emission 505-550 nm, and propidium iodide excitation at 543 nm, emission >560 nm. Maximum projection images of z series are shown.

Determination of Caspase-3 Activation-- Cytosolic aspartate-specific proteases, called caspases, are responsible for the deliberate disassembly of a cell into apoptotic bodies. Caspases are present as inactive pro-enzymes, most of which are activated by proteolytic cleavage. Both caspase-8 and caspase-9 can activate caspase-3 by proteolytic cleavage, which can in turn cleave vital cellular proteins leading to apoptosis (40). In this study, we have determined caspase-3 activity as an indicator of apoptotic induction. After challenge with appropriate agonists, 1 × 106 cells (including those that had dislodged from the adherent monolayer) were harvested by centrifugation for 30 s at 100 × g, and the pellets were resuspended in lysis buffer (20 mM Tris-HCl, 150 mM NaCl, 1 mM dithiothreitol, 5 mM EDTA, 5 mM EGTA, 1% Triton X-100, pH 7.5), incubated for 15 min at 37 °C, and centrifuged at 12,000 × g for 20 min at 4 °C. To assess supernatant caspase-3-like activity, 0.3 ml of lysate was combined with buffer (100 mM NaHEPES, 10% glycerol, 1 mM EDTA, 5 mM dithiothreitol, pH 7.5) and colorimetric caspase-3 substrate (IETD-pNA) to a final concentration of 20 µM. Samples were incubated in the dark at 37 °C, and absorbance was measured at 400 nm at 10-min intervals using a PerkinElmer Life Sciences spectrophotometer. Data were plotted and slopes calculated along the linear portion of the curve (at least three separate measurements). Data are presented as slope in arbitrary units and are expressed as the arithmetic means ± S.E. of the mean (n = 3). Statistical analysis was by Student's t test.

Determination of Cell Numbers-- Cells were harvested following incubation for the appropriate period by washing the monolayers in PBS and adding 0.05% trypsin, 0.02% EDTA solution for 2-5 min, and the single cell suspension counted using a Coulter CounterTM model Z1. Results are expressed as the mean cell number (± S.E.) harvested from a single well (n = 3, 3 replicates per test group). Statistical analysis was by Student's t test.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Detection of the Human Recombinant P2Y1 Receptor and the G Protein alpha  Subunit Complement of Astrocytoma (1321N1) Cells-- The heterologous expression of the human recombinant P2Y1 receptor in astrocytoma cells (1321N1) was confirmed by immunocytochemistry as well as by Western analysis using an anti-peptide antibody directed against the COOH-terminal tail of the human P2Y1 receptor. This antibody is selective for the P2Y1 receptor subtype and recognizes both the human and rat orthologues. Fixed cells incubated without the primary antibody showed no detectable staining, whereas those incubated with the anti-P2Y1 receptor antibody showed marked fluorescence that was localized to the membrane surface (Fig. 1A). Whole cell protein extracts prepared from the selected clonal line showed concentration-dependent immunoreactivity following Western analysis with the P2Y1 receptor-specific antibody (Fig. 1B). The electrophoretic mobility of the broad band detected had an apparent molecular mass of 45-55 kDa. No detectable staining was observed following Western analysis of protein from wild-type 1321N1 astrocytoma cells (data not shown). Whole cell extracts from astrocytomas expressing human P2Y1 receptors were also analyzed using antibodies specific for some relevant subtypes of the alpha  subunits of G proteins (Fig. 1C). Immunoreactive bands of the predicted molecular masses were identified for Galpha 13, Galpha o, and the short form of Galpha s. A double band was detected using an antibody that cross-reacts with both Galpha q and Galpha 11. No detectable immunoreactivity was observed with an antibody specific for Galpha i2, but a strong band was observed following analysis with an antibody that recognizes all three forms of Galpha i.


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 1.   Detection of the heterologously expressed human recombinant P2Y1 receptor and the complement of G protein alpha  subunits in 1321N1 astrocytoma cells. A, immunocytochemical localization of the human P2Y1 receptor expressed in astrocytoma cells was determined using the COOH-terminally directed anti-P2Y1 receptor antibody (1:200 dilution) in the presence of Triton X-100. Control cells were incubated without primary antibody. Scale bar, 50 µm. B and C, whole cell protein extracts prepared from 1321N1 cells were electrophoretically separated on 10% polyacrylamide gels. Following transfer onto nitrocellulose, the membranes were probed either with serial dilutions of the anti-P2Y1 receptor antibody (B) or with antibodies directed against the alpha  subunits of G proteins (at 1:250 dilution except for s1 that was at a 1:100 dilution) (C). The electrophoretic mobilities of marker proteins are also shown (arrows). The data are representative of at least three separate experiments.

P2Y1 Receptor-mediated Effects on the Phosphorylation Status of MAP Kinases-- To determine changes in the phosphorylation status of the different MAP kinases upon activation of the human P2Y1 receptor, whole cell protein extracts were analyzed by Western blotting using antibodies specific for the dually phosphorylated kinases and hence active forms. In serum-starved astrocytoma cells expressing the P2Y1 receptor, the immunoreactivity detected with antibodies selective for ERK1, ERK2, p38, and the SAPK isoforms, independent of their phosphorylation status, showed the expression of these proteins to be unaffected over the time course studied (up to 4 h) and by the application of the potent P2Y1 receptor agonist, 2-MeSADP (300 nM) (Fig. 2). A single species could be detected with the antibody to p38, and ERK1 and ERK2 had the predicted molecular mass of 44 and 42 kDa, respectively. However, several distinct entities could be observed following detection with the anti-SAPK antibody. The p54 and p46 members of this kinase family were apparent. Other immunoreactive bands were also detected with mobilities corresponding to 45 and 48 kDa (Fig. 2B).


View larger version (77K):
[in this window]
[in a new window]
 
Fig. 2.   Effect of 2-MeSADP on the phosphorylation status of ERK1 and ERK2 (A) or p38 and SAPKs (B) in astrocytoma cells heterologously expressing P2Y1 receptors. Whole cell extracts were prepared from cells that had been serum-starved for 4 h (T0) before incubation with incomplete media (Basal) or 2-MeSADP (300 nM) for the times shown in minutes. Samples were analyzed by Western detection following separation on 10% polyacrylamide gels. Consistency of protein loading was substantiated by determining the immunoreactivity of samples with phosphorylation state independent antibodies (top panels). Phosphorylation changes were demonstrated by detection with an antibody to ERK1 and ERK2 that recognizes only the dually phosphorylated (at Thr202 and Tyr204) and hence active forms (ERK-P). Similarly, SAPK and p38 activations were assessed using antibodies specific for the doubly phosphorylated forms of all isoforms at residues Thr183 and Tyr185 (p46-P and p54-P shown) or Thr180 and Tyr182 (p38-P), respectively.

Under basal conditions over the time course studied, a slight phosphorylation of ERK1 and ERK2 was detected that peaked 10 min following application of the vehicle control and which had declined to undetectable levels by 1 h (Fig. 2A). Application of 2-MeSADP (300 nM) induced a marked and rapid phosphorylation of both ERK kinases that was detectable after 5 min and had reached a maximal response at 15 min. Although the level of phosphorylation subsequently declined, that detected 4 h following drug application remained elevated over basal (Fig. 2A). To substantiate the consistency of protein content, the immunoreactivity of samples was also determined using phosphorylation state-independent anti-ERK antibodies (Fig. 2A).

The phosphorylation of p38 in serum-starved 1321N1 cells was only just detectable using the phosphospecific antibody, and the level of this activity remained unchanged throughout the time course investigated following application of either vehicle control (basal) or 2-MeSADP (300 nM) (Fig. 2B). Differential levels of phosphorylation were detected for the SAPKs after serum starvation and that observed for the isoform with apparent molecular mass of 45 kDa was much more pronounced than that for the other SAPK isoforms present (46, 48, and 54 kDa). Following application of vehicle alone, none of the isoforms showed any change in their activity status over the 4-h period investigated (Fig. 2B). A transient increase in the phosphorylation of the 45-, 46-, and 54-kDa forms was observed upon application of 2-MeSADP (300 nM), reaching a maximum by 15 min and returning to basal levels by 1 h (Fig. 2B). In contrast, the activity status of the 48-kDa isoform remained unaffected by 2-MeSADP (300 nM) over the time course studied. The level of immunoreactivity using phospho-independent antibodies was comparable for p38 and the p45 and p54 forms of the SAPKs. The level detected for the remaining SAPK isoforms, however, was much lower, particularly that with a molecular mass of 46 kDa. The levels of the p38 and the SAPK proteins were essentially constant across the time course studied and between basal and 2-MeSADP-treated groups (Fig. 2B).

Effects of an Adenosine Triphosphate and ADP-- Activation of the human recombinant P2Y1 receptor by 2-MeSATP or by ADP (0.1-10 µM) induced concentration-dependent phosphorylation changes in ERK1 and ERK2 (Fig. 3A). However, in contrast to that evoked by 2-MeSADP (300 nM), the enhanced immunoreactivity was transient in duration, with increased phosphorylation detected at 15 min but not following 120 min of exposure to either ADP or 2-MeSATP, even at the highest concentration tested (Fig. 3A). The level of ERK1 and ERK2 protein content was consistent across the different treatment groups (Fig. 3A). A concentration dependence was again observed in the phosphorylation of the SAPK isoforms induced by either ADP or 2-MeSATP application for 15 min (Fig. 3B). In addition, the same isoforms of the SAPKs were activated by both ligands, effects that were identical to those stimulated by 2-MeSADP (Fig. 3B). Neither ADP nor 2-MeSATP, over the concentration range tested, had any effect on the phosphorylation status of p38 (Fig. 3B) or on the expression levels of the proteins (Fig. 3). The phosphorylation status of all MAP kinases was unaffected following application of the adenosine nucleotides to wild-type astrocytoma cells (Fig. 3C).


View larger version (48K):
[in this window]
[in a new window]
 
Fig. 3.   Effect of 2-MeSATP, ADP, or carbachol on the phosphorylation status of the MAP kinases in astrocytoma cells. Whole cell extracts were prepared from (A and B) 1321N1 cells heterologously expressing human P2Y1 receptors, which had been serum-starved for 4 h before incubation with increasing concentrations of ADP or 2-MeSATP (µM) for the times shown. C, wild-type 1321N1 cells following serum starvation were incubated in the presence of incomplete media (CON), 2-MeSADP (MeS, 300 nM), or carbachol (CAR, 10 mM) for the times shown. Changes in MAP kinase activity status were demonstrated by detection with an antibody to the phosphorylated forms of (A and C) ERK1 and ERK2 (ERK-P) or to (B and C) the isoforms of the SAPK (p46-P and p54-P shown) and p38 (p38-P) families. Consistency of protein loading following Western analysis was substantiated by determining the immunoreactivity of samples with phosphorylation state independent antibodies (A, top panel and B, left panel).

Effect of Endogenous Muscarinic Receptors-- To determine if endogenous Gq-coupled receptors can trigger changes in the activities of the MAP kinases similar to those stimulated by the recombinant P2Y1 receptor, the effect of carbachol was examined. Native muscarinic receptors have been shown to be functionally active in 1321N1 astrocytoma cells (41). Carbachol (10 mM) induced an increase in the phosphorylation of ERK1 and ERK2 over basal levels in wild-type 1321N1 cells following exposure for either 15 or 120 min (Fig. 3C). In addition, a marked increase was observed in the activity of the 45-kDa SAPK isoform (Fig. 3C). However, in contrast to that evoked by 2-MeSADP in cells stably expressing the recombinant P2Y1 receptor, the enhanced immunoreactivity was observed at both 15 and 120 min. No change could be detected at either time point examined in the phosphorylation status of any of the other SAPK isoforms detected or of p38 (Fig. 3C). Similar immunoreactive changes were observed following carbachol treatment in the astrocytoma cells expressing the recombinant P2Y1 receptor (data not shown). The level of the MAP kinase protein content was consistent across the different treatment groups in the wild-type astrocytoma cells and showed an expression pattern that was identical to that observed in the transfected line (Fig. 3).

2-MeSADP Concentration-Response Relationship and Antagonism of the P2Y1 Receptor-mediated Phosphorylation of MAP Kinases-- The concentration dependence of the phosphorylation changes induced by 2-MeSADP at the human recombinant P2Y1 receptor was determined at the peak of the transient response (15 min) and also during the sustained phase of the MAP kinase activity profiles (2 h). Enhanced immunoreactivity was observed using the anti-phosphospecific ERK antibody, in samples from 1321N1 cells incubated for 15 min with increasing concentrations of 2-MeSADP, until a maximal response was obtained at 30 nM (Fig. 4A). At 120 min (sustained phase), the phosphorylation of ERK1 and ERK2 also increased in a concentration-dependent manner, with a maximal response at and above 100 nM 2-MeSADP (Fig. 4B). In contrast, the phosphorylation of the SAPK isoforms at 15 min continued to increase over the entire concentration range of 2-MeSADP used (1-1000 nM) (Fig. 5A). Phosphorylation of p38 and the 48-kDa isoform of SAPK remained unchanged over basal levels following incubation for 15 min with increasing concentrations of 2-MeSADP (up to 1 µM). In addition, no changes were observed in the phosphorylation states of p38 or any of the SAPK isoforms at 120 min over the concentration range of 2-MeSADP examined (Fig. 5B). At all 2-MeSADP concentrations used in this study the level of expression of the MAP kinases was unaffected (Figs. 4 and 5).


View larger version (55K):
[in this window]
[in a new window]
 
Fig. 4.   Antagonism of the 2-MeSADP-mediated phosphorylation of ERK1 and ERK2 in astrocytoma cells heterologously expressing P2Y1 receptors. Whole cell extracts were prepared from serum-starved cells (for 4 h) that had been incubated with and without the P2Y1 receptor-selective antagonist, A2P5P (10 µM), for 30 min before 15-min (A) or 120-min (B) incubation with increasing concentrations of 2-MeSADP (nM). Consistency of protein loading was substantiated by determining the immunoreactivity of samples with phosphorylation state independent anti-ERK antibodies (top panels). Phosphorylation changes were demonstrated by detection with an antibody to ERK1 and ERK2 that recognizes only the dually phosphorylated and hence active forms (ERK-P).


View larger version (47K):
[in this window]
[in a new window]
 
Fig. 5.   Antagonism of the 2-MeSADP-mediated phosphorylation of SAPKs in astrocytoma cells heterologously expressing P2Y1 receptors. Whole cell extracts were prepared from serum-starved cells that had been incubated with and without A2P5P (10 µM) for 30 min before 15-min (A) or 120-min (B) incubation with increasing concentrations of 2-MeSADP (nM). Consistency of protein loading was substantiated by determining the immunoreactivity of samples with phosphorylation state independent antibodies to p38 and the SAPKs (top panels). Phosphorylation changes were demonstrated by detection with an antibody to p38 that recognizes only the dually phosphorylated (at Thr180 and Tyr182) and hence active forms (p38-P). Similarly, SAPK activation was assessed using an antibody specific for the doubly phosphorylated forms of all SAPK isoforms at residues Thr183 and Tyr185 within the TPY sequence.

To confirm that changes in the phosphorylation state of the MAP kinases observed upon application of 2-MeSADP were due to the activation of the heterologously expressed P2Y1 receptor, the transfected cells were preincubated with the P2Y1 receptor-specific antagonist, A2P5P (10 µM), for 30 min. Phosphorylation of ERK1 and ERK2 induced by a 15-min incubation with 2-MeSADP was abolished over the agonist concentration range 1-100 nM in cells pretreated with the antagonist and partially inhibited when using the agonist at concentrations of 300 nM or greater (Fig. 4A). The activation of the SAPK isoforms induced by 2-MeSADP at 15 min was similarly abolished by pretreatment with A2P5P (10 µM) at all concentrations of agonist tested (Fig. 5A). The activity of the 48-kDa SAPK isoform and of p38 was unaffected by treatment with the P2Y1 receptor-selective antagonist. Phosphorylation of ERK1 and ERK2 induced by incubation with 2-MeSADP (1-1000 nM) for 120 min was also greatly attenuated in cells pretreated with A2P5P (Fig. 4B), whereas basal phosphorylation of p38 and all the SAPK isoforms observed at this time point remained unchanged (Fig. 5B). The antagonist had no effect on the expression levels of the MAP kinases or on their basal phosphorylation status at the times investigated (Fig. 6).


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 6.   Effect of the antagonist, A2P5P, on the basal activity status of MAP kinases in astrocytoma cells heterologously expressing P2Y1 receptors. Whole cell extracts were prepared from serum-starved astrocytoma cells (for 4 h) that had been treated in the absence (CON) or presence of A2P5P (10 µM) for 30 min before a further 15- or 120-min incubation with incomplete media. Consistency of protein loading was substantiated by determining the immunoreactivity of samples with phosphorylation state independent antibodies to ERK1 and ERK2 (A) or the SAPKs and p38 (top panels) (B). Detection with the phospho-specific antibodies is shown in the lower panels following long exposure times of the autoradiographic film.

Effect of MEK1, PKC, Src, and PI 3-K Inhibitors on the Induced Phosphorylation of ERK1 and ERK2 by P2Y1 Receptors Expressed in 1321N1 Cells-- The effect of selective inhibitors of MEK1 (PD 98059, 20 µM), Src (PP1, 200 nM), PI 3-K (LY 294002, 100 µM), or PKC (Gö 6976 for Ca2+-dependent isoforms, 10 nM, and Ro 32-1432 for all isoforms, 50 nM) on the phosphorylation of ERK1 and ERK2 induced by 2-MeSADP (50 nM) was examined. Preincubation of the cells with these inhibitors for 10 min had no observable effect on basal levels of ERK phosphorylation obtained at 15 min (Fig. 7A). The 2-MeSADP-induced phosphorylation at 15 min was greatly inhibited by pretreatment with the PI 3-K or Src inhibitors as well as by either of the PKC inhibitors. PD 98059 at the concentration used was less effective in reducing the 2-MeSADP-induced phosphorylation (Fig. 7A). Basal levels of ERK phosphorylation observed at 120 min were unaffected by preincubation with LY 294002, PP1, or PD 98059 (Fig. 7B), whereas that induced by 2-MeSADP was abolished by LY 294002 and PD 98059 but unaffected by PP1 (Fig. 7B). In contrast, both protein kinase C inhibitors increased basal levels of ERK phosphorylation, comparable to that observed following activation by 2-MeSADP (Fig. 7B). This enhanced basal activity of ERK1 and ERK2 after a 2-h period in the presence of the PKC inhibitors was also evident in non-transfected astrocytoma cells (data not shown). The expression levels of ERK1 and ERK2 were unaffected by the kinase inhibitors at both time points examined (Fig. 7).


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 7.   Effect of various kinase inhibitors on the 2-MeSADP-mediated phosphorylation of ERK1 and ERK2 in astrocytoma cells heterologously expressing P2Y1 receptors. Whole cell extracts were prepared from serum-starved astrocytoma cells (for 4 h) that had been treated with the following inhibitors for 10 min before 15-min (A) or 120-min (B) incubation with 2-MeSADP (MeS, 50 nM) or incomplete media (Basal): LY 294002 (LY, 100 µM), PD 98059 (PD, 20 µM), PP1 (200 nM), Gö 6976 (, 10 nM) or Ro 32-1432 (Ro, 50 nM). Basal phosphorylation without inhibitors present is shown (CON). Consistency of protein loading was substantiated by determining the immunoreactivity of samples with phosphorylation state independent anti-ERK antibodies (top panel). Phosphorylation changes were demonstrated by detection with an antibody to ERK1 and ERK2 that recognizes only the dually phosphorylated and hence active forms (ERK-P).

Effect of a Dominant Negative Mutant of Ras or Pertussis Toxin Pretreatment on P2Y1 Receptor-mediated ERK Phosphorylation-- To evaluate the involvement of Ras in mediating the activation of ERK by P2Y1 receptors, transient expression of the dominant negative mutant of RasAsn-17 was performed. This Ras mutant, in which amino acid 17 (serine) is changed to asparagine, is thought to function by inhibiting guanine nucleotide exchange factors (42). The increase in RasAsn-17 levels following transfection was evaluated by immunoblotting cell extracts immediately prior to drug addition with a polyclonal antibody to Ras. The inset in Fig. 8B shows that in mock-transfected cells the immunoreactivity with the anti-Ras antibody was almost undetectable, compared with the intense reactivity obtained from the same number of cells transfected with pUSEamp(+) plasmids containing dominant negative Ha-RAS. The transfection efficiency for all experiments was between 46 and 52%. The level of phosphorylation of ERK1 and ERK2 induced by a 15- or 120-min application of 2-MeSADP (50 nM) was unchanged by transfection with the empty plasmid (Fig. 8, A and B). However, following transient expression of RasAsn-17, the 2-MeSADP-induced phosphorylation at 15 min (Fig. 8A) was decreased but unaffected at 120 min (Fig. 8B). Neither transfection with pUSEamp or pUSEamp(RASAsn-17 showed any effect on basal levels of ERK phosphorylation observed at 15 or 120 min (Fig. 8, A and B). To show consistency in protein loading, detection of ERK1 and ERK2 using phosphorylation state-independent pan antibodies was also performed (Fig. 8, A and B).


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 8.   Effect of dominant negative Ras or pertussis toxin on the phosphorylation of ERK1 and ERK2 and the effect of dominant negative MKK4 on SAPK activation in cells expressing P2Y1 receptors. Whole cell extracts were prepared from 1321N1 cells that had been transiently transfected either with the empty plasmid (Mock) or the plasmid incorporating dominant negative Ha-RAS RASAsn-17 48 h prior to incubation for 15 min (A) or 120 min (B) in incomplete media (CON) or 2-MeSADP (MeS, 50 nM). The effect of these agents on the phosphorylation status of ERK1 and ERK2 (ERK-P) in non-transiently transfected cells is also shown. All cells were serum-starved for 4 h prior to the application of 2-MeSADP. Consistency of protein loading was substantiated by the regular intensity of the immunoreactivity obtained following detection of the samples shown with the anti-ERK antibodies (ERK). The Western blots are representative of two separate transfections, and each panel has been taken from a single immunoblot. The inset shows an immunoblot of protein from cell samples extracted immediately prior to drug addition that had been transiently transfected with either pUSEamp (Mock) or pUSEamp incorporating dominant negative Ha-RAS (RASAsn-17). Following separation by 15% polyacrylamide gel electrophoresis and transfer onto nitrocellulose, detection was made with an anti-beta -actin antibody to demonstrate consistency of protein loading (not shown) as well as with an antibody to Ras. C, whole cell protein extracts were prepared from 1321N1 cells incubated for 15 min with incomplete media (CON) or 2-MeSADP (MeS, 50 nM) following pertussis toxin pretreatment (PTX, 18 h at 100 ng ml-1) and analyzed by Western blotting using phospho-specific anti-ERK antibodies (ERK-P). D, whole cell extracts were also prepared from cells that had been transiently transfected either with the empty plasmid (Mock) or that incorporating dominant negative MKK4 48 h prior to incubation for 15 min in incomplete media (CON) or 2-MeSADP (MeS, 300 nM). The effect of these agents on the phosphorylation status of the SAPKs and p38 is shown together with data from non-transiently transfected cells. The Western blot is a representative from two separate transfections. The inset shows the level of expression of MKK4 immediately prior to drug addition.

Preincubation of the clonal 1321N1 cells with pertussis toxin (100 ng ml-1 for 18 h) had no observable effect on basal levels of ERK phosphorylation obtained at 15 min (Fig. 8C). The 2-MeSADP-induced phosphorylation (50 nM) was also unaffected by treatment with the toxin (Fig. 8C). The level of expression of ERK1 and ERK2 protein was unchanged by pertussis toxin pretreatment (Fig. 8C).

Effect of a Dominant Negative Mutant of MKK4 on P2Y1 Receptor-mediated SAPK Phosphorylation-- SAPKs are activated by phosphorylation on threonine and tyrosine within the activation motif by one of two cloned dual specificity kinases, MKK4 and MKK7. These kinases are in turn activated by an MKKK, of which several examples have been identified. Transient expression (54% efficiency) of a dominant negative mutant of MKK4 in astrocytoma cells was found to decrease the levels of SAPK phosphorylation induced by a 15-min application of 2-MeSADP (300 nM), compared with mock-transfected controls (Fig. 8D). However, the suppression of the activity status of the higher molecular weight SAPK species appeared to be greater than for the isoform with apparent molecular mass of 45 kDa (Fig. 8C). Expression of the mutant MKK4 protein was determined by immunoblotting the transient transfected cell extracts immediately prior to 2-MeSADP addition. The immunoreactivity with the anti-MKK4 antibody was weak in mock-transfected cells compared with the intense reactivity obtained from the same number of cells transfected with pCMV-MKK4(K95R) (inset, Fig. 8D). The pattern of 2-MeSADP-induced SAPK phosphorylation was similar in cells containing the empty plasmid compared with those that had not been transiently transfected (Fig. 8D). Transfection with either plasmid showed no apparent effect on basal levels of SAPK phosphorylation observed at 15 min (Fig. 8D).

Regulation of Transcription Factors by the Human P2Y1 Receptor-- Phosphorylation of transcription factors is a prerequisite for their activation (43). By using phospho-specific antibodies, the regulation of c-Jun, activating transcription factor-2 (ATF-2) and Elk-1 by the recombinant P2Y1 receptor, was determined using Western analysis of whole cell extracts from the P2Y1 receptor-expressing cell line. Phosphorylation of the transcription factors c-Jun and Elk-1 was detectable under basal conditions following incubation with incomplete media and remained unchanged over the time course investigated (Fig. 9A). There was only faint immunoreactivity detectable at all time points examined under basal conditions using antibodies to phosphorylated ATF-2. Incubation with 2-MeSADP (300 nM) had no effect on the basal immunoreactivity detected for c-Jun or ATF-2 over the time course investigated (Fig. 9A). However, 2-MeSADP increased the phosphorylation of Elk-1 over time, reaching a maximal response following 60 min of agonist application and which was maintained throughout the duration of the time course (Fig. 9A). The level of expression of the transcription factors was unaffected by the application of 2-MeSADP and unchanged over the period investigated (data not shown). The phosphorylation of Elk-1 induced by 2-MeSADP at 60 min was inhibited by a 10-min preincubation with PD 98059 (20 µM). Basal levels of Elk-1 phosphorylation at this time point were also slightly inhibited by the MEK1 inhibitor (Fig. 9B). The expression levels of Elk-1 were unaffected by all treatments (Fig. 9B).


View larger version (35K):
[in this window]
[in a new window]
 
Fig. 9.   Effect of 2-MeSADP on the phosphorylation of transcription factors in astrocytoma cells heterologously expressing P2Y1 receptors. A, whole cell extracts were prepared from serum-starved cells (T0) that had been incubated in the presence of incomplete media (Basal) or 2-MeSADP (300 nM) for the times shown (minutes). Activation of the transcription factors Elk-1, c-Jun, and ATF-2 was determined using antibodies that recognize the phosphorylated forms of the proteins. B, samples were analyzed for Elk-1 expression (left panel) or with an antibody recognizing the phosphorylated form of Elk-1 (right panel) from cells preincubated with or without PD 98059 (PD, 20 µM) for 10 min before a 60-min incubation with either incomplete media (CON) or 2-MeSADP (MeS, 300 nM).

Induction of Apoptosis but Not Cell Proliferation by the Human Recombinant P2Y1 Receptor and Effect of Ras and MKK4 Dominant Negative Mutants-- Following treatment for 5 h with either 2-MeSADP (300 nM) (Fig. 10A) or staurosporin (300 nM) (data not shown), some astrocytoma cells fluoresced brightly in the presence of annexin V-FITC which were not counterstained by propidium iodide. In these cells FITC green fluorescence patches could be observed by confocal microscopy that were located on the cell surface (Fig. 10, B and C). None of the control cells incubated in media alone showed any detectable annexin V binding at this time point (data not shown). Activation of caspase-3 following stimulation of P2Y1 receptors was also determined. Caspase-3 activity within cell lysates (measured by the hydrolysis of a colorimetric substrate peptide) increased as a function of time following treatment of cells with 2-MeSADP (300 nM) and was significantly above that in samples incubated for 3 h and more with media alone (Fig. 10D). In addition, activation of caspase-3 activity by 2-MeSADP was attenuated by A2P5P (10 µM) (Fig. 10D). A2P5P had no effect on basal caspase activity (data not shown).


View larger version (55K):
[in this window]
[in a new window]
 
Fig. 10.   Effect of 2-MeSADP on annexin V binding, caspase-3 activation, and the proliferation of astrocytoma cells heterologously expressing P2Y1 receptors. Annexin V binding to astrocytoma cells expressing human P2Y1 receptors following incubation for 5 h with 2-MeSADP (300 nM) as detected by low power fluorescence microscopy (scale bar, 50 µm) (A) or confocal microscopy (B and C) which shows a cluster of annexin V-positive cells (green) in the center of the field of the propidium iodide-stained cells (red), where B is a single channel overlay confocal image (scale, 146.2 × 146.2 µm), and C is a single overlay of a group of apoptotic cells taken from z series (scale, 59 µm × 59 µm). D and E, in vitro caspase-3-like protease activity was determined using a colorimetric caspase-3 substrate peptide. D, cell lysates were prepared at the indicated times after incubation of astrocytoma cells in incomplete media (Basal, open histograms), 2-MeSADP (300 nM, closed histograms), or 2-MeSADP (300 nM) following a 30-min preincubation with A2P5P (10 µM, hatched histograms). Values are expressed in arbitrary units as the mean ± S.E. (n = 3). Groups labeled * are significantly different from basal (p < 0.001) and groups labeled # are significantly different from those incubated with 2-MeSADP alone. E, caspase-3 activity was determined 5 h following incubation in incomplete media (Basal, open histograms) or 2-MeSADP (300 nM, closed histograms) with or without a 10-min preincubation with inhibitors of Src (PP1, 200 nM), PI 3-K (LY 294002, 100 µM), MEK1 (PD 98059, 20 µM), or the classical PKC isoforms (Gö 6976, 10 nM). Data are also shown for cells transfected 48 h prior to drug addition with either dominant negative Ras or MKK4 mutants. Groups labeled * are significantly different from that without inhibitors present (p < 0.01), and the group labeled # is significantly different from the same treatment but in non-transiently transfected cells. F, the mean number of cells harvested from a single well, 24 h following application of incomplete media (Basal, open histogram) or 2-MeSADP (300 nM, closed histogram). Groups labeled mock had been transfected 48 h previously with an empty vector, and those labeled MKK4 had been transfected with the vector containing the kinase-deficient mutant of MKK4. Values are expressed as the mean cell number ± S.E. (n = 2, four replicates). The group labeled * is significantly different from basal (p < 0.01). G, the mean number of cells harvested from a single well, 24 h following application of incomplete media (Basal, open histogram), 2-MeSADP (300 nM, closed histogram), fetal calf serum (FCS, 1%; hatched histograms), 2-MeSADP (at 0.3 or 3 µM) in the presence of 1% serum (MeS + FCS, shaded histograms), carbachol (10 mM, striped histogram) or 2-MeSADP (300 nM) in the presence of carbachol (MeS + CAR, crossed histogram). Values are expressed as the mean cell number ± S.E. (n = 3, four replicates). Groups labeled * are significantly different from basal (p < 0.01) and that labeled # is significantly different (p < 0.01) from that incubated in the presence of carbachol alone.

The effects of selective inhibitors and of the dominant negative mutants of Ras and MKK4 were also determined on the ability of 2-MeSADP to induce caspase-3 activity. Astrocytoma cells expressing the recombinant P2Y1 receptor were pretreated for 10 min with PD 98059 (20 µM), PP1 (200 nM), LY 294002 (100 µM), or Gö 6976 (10 nM) before a further 5-h incubation with or without 2-MeSADP (300 nM) present. Basal caspase-3 activity and that induced by 2-MeSADP at this time point were unaffected by PPI, PD 98059, or Gö 6976 but were increased slightly in the presence of the PI 3-K inhibitor (Fig. 10E). Transfection of cells (48 h prior to the addition of 2-MeSADP) with dominant negative forms of either Ras or MKK4 had no significant effect on basal levels of caspase-3 activity compared with mock-transfected cells (data not shown) and were similar to the values obtained for non-transfected cells expressing the P2Y1 receptor (Fig. 10E). Dominant negative Ras expression also had no effect on the caspase-3 activity induced by 2-MeSADP, whereas the kinase-deficient MKK4 mutant partially blocked this latter response (Fig. 10E).

The ability of 2-MeSADP to modulate the proliferative outcome of astrocytoma cells expressing the recombinant P2Y1 receptor was also assessed. Application of 2-MeSADP (300 nM) in the absence of other exogenously administered mitogenic factors showed a small but significant decrease in the number of cells counted 24 h later, as compared with basal, which was not observed in cells transiently transfected with the MKK4 mutant (Fig. 10F). In contrast, fetal calf serum (1%) caused a significant increase in cell number (Fig. 10G) that was unaffected by the addition of 2-MeSADP at concentrations of 0.3 or 3 µM (Fig. 10G). A marked increase in cell number was also obtained following application of carbachol (10 mM) that was attenuated by the presence of 2-MeSADP (300 nM) (Fig. 10G).

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In this study, we have examined the ability of the human P2Y1 receptor to stimulate the MAP kinase transduction cascades and to determine if this activity could be correlated with transcription factor phosphorylation or the proliferative outcome of the host cell. Whereas a stably transfected cell line was employed for these studies, the host cell was derived from a human type (astrocytic), which in its original parent state expressed functional P2Y1 receptors (18) and hence should contain the appropriate native transductional components for the recombinant receptor. The presence of P2Y1 as the sole P2Y receptor has enabled the transduction cascades of an identified receptor type to be characterized. Definitive receptor specificity was also confirmed by the suppression of the stimulated responses by a P2Y1 receptor-selective antagonist. Expression of the P2Y1 receptor protein at the cell membrane of the transfected cells was demonstrated by immunocytochemistry, using an anti-peptide antibody specific for the human P2Y1 receptor subtype. The size of the immunoreactive band detected in Western blots of the astrocytoma cells is consistent with the known polypeptide size of the P2Y1 receptor (373 amino acids, 42 kDa) and its glycosylation (1).

Functional responses of the P2Y1 receptor have been shown to be mediated through G11 and/or Gq proteins, which were shown to be expressed by the astrocytoma host cells used in this study. Upon agonist stimulation, G protein-coupled receptors transduce their effects through both the GTP-bound Galpha and the dissociated Gbeta gamma component of the heterotrimeric G protein, regulating directly downstream effectors (44) including adenylate cyclases, phospholipase C isoforms, ion channels, PI 3-K (45), and Tec family tyrosine kinases (46). Several G protein-coupled receptors have been shown to stimulate the ERK pathway through a variety of G protein subunits. In the case of the Gq/11-coupled m1 muscarinic acetylcholine and alpha 1-adrenergic receptors, the activation of ERK is mediated mainly by Galpha q/11. In contrast, Gi-coupled m2 muscarinic acetylcholine, alpha 2-adrenergic, somatostatin sst2, and the Gs-coupled beta -adrenergic receptors, all induce ERK activation through Gbeta gamma release and the subsequent stimulation of tyrosine kinases such as Src (47, 48). The pathways downstream of G protein coupling have not previously been established for any molecularly defined P2Y receptor subtype. In the present report, the potential actions of nucleotides at the P2Y1 receptor in stimulating the MAP kinase cascades were investigated. The P2Y1 receptor had no effect on the activity status of p38 kinase but caused a marked phosphorylation of the SAPK and the ERK cascades. For the ERK cascade, this was shown to be via a pertussis toxin-insensitive pathway through a number of transduction mediators including PKC, PI 3-K, and Src, with apparent cooperative effects.

The mechanisms by which Gi- and Gq-coupled receptors typically activate ERK are through Ras-dependent or protein kinase C-dependent pathways, respectively. However, several exceptions to this rule have been reported for Gq-coupled receptors, in that ERK can be activated through a pertussis toxin-insensitive and PKC-independent pathway (49). The recombinant P2Y1 receptor utilizes transduction cascades to activate ERKs that are thus commonly associated with Gq-linked receptors (PKC activation) in addition to the recruitment of Src implying some Ras dependence, which is more typical of Gi-coupled receptors. An involvement of Ras in the mediation of the P2Y1 receptor-induced ERK activity was demonstrated in this study by overexpression of a dominant negative Ras mutant. However, although inhibition of Src or Ras attenuated the transient phase of the ERK activity profile, these transduction effectors did not seem necessary for the sustained activation of ERK. This differential requirement for transduction mediators during the time course of ERK activation has also recently been demonstrated for the Gi/o-coupled somatostatin sst4 receptor in which the acute phase is both Src- and Ras-dependent, but the prolonged ERK response is mediated by protein kinase C (50). The mobilization of Ca2+ through the P2Y1 receptor could account for the stimulation of the Ca2+-dependent PKC isoforms that have been shown to activate the ERK cascade at the point of Raf (51) and thus through a Ras-independent mechanism.

The PI 3-K pathway is also important for regulating ERK activity by a number of mechanisms that have been shown to occur both upstream and downstream of Ras (52, 53). The sustained phase of ERK phosphorylation mediated through the P2Y1 receptor was abolished following application of a PI 3-K inhibitor, whereas the transient phase was only partially dependent on this kinase activity. It thus appears that the transient activation of ERK by the P2Y1 receptor is mediated through the cooperative effects of Src, Ras, Ca2+-dependent PKC isoforms as well as PI 3-K, whereas the sustained phase requires only PI 3-K activity (and possibly PKC). This mechanism may be similar to that reported for Gi protein-coupled receptors that have been shown to activate ERK via a Ras-independent pathway through PI 3-Kgamma and PKCxi (54). Stimulation of PKC isoforms in addition to their requirement for allosteric activators has recently been shown to be critical on subsequent phosphorylation, possibly through the PI 3-K-dependent kinase, PDK1 (55). In accord with this concept is the finding that ERK phosphorylation by the P2Y1 receptor requires PI 3-K for both the acute and sustained phases. We could not conclude if the sustained phase of ERK activation is additionally mediated via PKC due to the marked increase in basal ERK activity observed in the presence of various PKC inhibitors. The cause of this ERK stimulation following prolonged PKC down-regulation has not been determined but could also be observed in non-transfected astrocytoma cells. The ineffectiveness of the MEK1 inhibitor at blocking the P2Y1 receptor-mediated transient activation of ERK1 and ERK2 may reflect the inability of PD 98059 to abolish high intensity signals (56). However, PD 98059 is a MEK1-selective inhibitor, and it is possible that ERK activation through P2Y1 receptors is primarily mediated through MEK2 in the early transductional events and via MEK1 for the sustained phase of stimulation.

The rapid and sustained phosphorylation of both ERK1 and ERK2 induced by the potent P2Y1 receptor agonist, 2-MeSADP, was abolished by the P2Y1 receptor-specific antagonist, A2P5P. The concentration dependence of this ERK activity was similar to that observed with 2-MeSADP for other functional responses mediated by this receptor type (EC50 values of the order of 10 nM) (9-11, 57). The natural ligand ADP, although less potent than 2-MeSADP, induced phosphorylation of ERK1 and ERK2 that was comparable to that evoked by 2-MeSATP, supporting recent evidence that uncontaminated adenosine triphosphates can serve as agonists at the recombinant P2Y1 receptor (10, 11). Release of ATP by cells in culture occurs very readily (1) and can also give rise to misleading results; this might have contributed to the transient and low degree of ERK1 and ERK2 stimulation observed in this study following incubation of the astrocytoma cells with incomplete media. However, the P2Y1 receptor-selective antagonist, A2P5P, showed no effect on the basal levels of ERK phosphorylation, suggesting that this activity may result directly from mechanical stimulation (34).

Although the Ras-ERK cascade is well documented for several G protein-coupled receptors, very little is known of any activation of the other MAP kinases, p38 and the SAPKs, by this receptor class. Activation of p38 has been shown in rat glomerular mesangial cells following stimulation with UTP and ATP, suggesting that this may be mediated through the P2Y2 receptor (27). In addition, a very recent report on native P2Y receptors in the endothelial cell line, EAhy926, has shown an unusual inhibition of a pre-stimulated SAPK and p38 activity mediated by UTP and suggested to be via P2Y2 or P2Y4 receptors (58). In the present study, we have shown differential activation of members of the SAPK family through the P2Y1 receptor but not of p38. The kinetic profiles of the SAPK isoforms activated, those with apparent molecular masses of 45, 46, and 54 kDa, were similar and transient, although a fourth immunoreactive band of 48 kDa that was identified by both the phospho-dependent and -independent SAPK antibodies remained unaffected by 2-MeSADP, ADP, or 2-MeSATP. Phosphorylation of the p54, p46, and p45 SAPK isoforms was inhibited by the P2Y1 receptor-specific antagonist, A2P5P. At least 10 SAPK isoforms have been identified that correspond to alternatively spliced isoforms derived from the JNK1, JNK2, and JNK3 genes (59). The consequence of the differential activation of the SAPK isoforms identified in the astrocytoma cells by the P2Y1 receptor remains to be determined, but possibly provides fine-tuning of various cellular events including apoptosis (see below). In addition, this differential activation suggests that discrete mechanisms are in place upstream of the individual SAPK family members. Stimulation of only the p45 form of the SAPKs by the muscarinic receptor agonist, carbachol, and the finding that this displayed a different kinetic profile to that induced by the P2Y1 receptor provide additional evidence that members of this MAP kinase family are regulated via distinct mechanisms in the same host cell.

Proximally, SAPKs are activated by a cascade of kinases (17), although the upstream regulators in this pathway are incompletely characterized. Tumor necrosis factor-alpha -stimulated SAPK activation is perhaps best described and involves recruitment of the adapter protein TRAF2 to the cytosolic portion of the ligated tumor necrosis factor-alpha receptor (60). Other intermediates have been proposed to play a role in different models of SAPK activation including oxidative stress, DNA damage, altered ion fluxes, and caspase proteases. However, the present study suggests that caspase-3 activation is not an obligatory step in the signaling pathway coupling P2Y1 receptors to SAPK activation, as this MAP kinase activity preceded the accumulation of active caspase-3 by several hours. It is possible that changes in intracellular Ca2+ (61) may be important for the P2Y1 receptor-mediated SAPK activation. SAPKs are activated by phosphorylation on threonine and tyrosine residues by one of two cloned dual specificity kinases, MKK4 and MKK7. The dependence on MKK4 for the activation of the p54 and p46 SAPK isoforms mediated by the P2Y1 receptor was substantiated by showing a decrease in their phosphorylation status following expression of a kinase-deficient MKK4 mutant. The induced phosphorylation of the p45 isoform by 2-MeSADP was only slightly affected by the MKK4 mutant, which may possibly reflect the achieved transient transfection efficiency or that MKK7 may be the preferred upstream regulator of this kinase.

The apparent lack of phosphorylation of c-Jun and of ATF-2 transcription factors, both known substrates for the SAPKs, suggests that the observed transient activation of these kinases, induced via the recombinant P2Y1 receptor, is insufficient for their cytoplasmic nuclear translocation. In every case studied so far, sustained ERK activation is required for nuclear-targeted transcription factor phosphorylation, although similar observations for the SAPK family have not as yet been reported. Consistent with this hypothesis is the demonstration that sustained ERK activity induced through the P2Y1 receptor produced Elk-1 phosphorylation. These data, taken together, thus suggest that the strength and duration of the stimulus to other MAP kinase family members can also be important determinants that govern the biological response to a particular receptor activation.

The functional responses mediated by events downstream from the activation of P2Y receptors are poorly understood. It has been suggested that prostacyclin production following activation via P2Y receptors on endothelial cells is via ERK activation (20), consistent with the mechanism utilized by endothelial cells to regulate vascular smooth muscle cell proliferation. Proliferative activity has been reported using UTP in C6 glioma cells through P2Y2 receptor-mediated stimulation of the Ras-ERK pathway (28). P2Y4 receptors in rat glomerular mesangial cells have been shown to induce proliferation (29), whereas stimulation via the P2X7 receptor induces apoptosis (32). ERK is almost universally stimulated by mitogens and cell survival factors such as growth factors, hormones, and cytokines and is intimately connected with the regulation of cell growth as well as differentiation. SAPK and p38 on the other hand are activated by various stressors such as chemical agents and ultraviolet irradiation, tumor necrosis factor, and interleukin-1, which appear to play a decisive role in the control of cell death. A necessary role of SAPK in apoptotic induction by UV irradiation, but not Fas receptor ligation, was demonstrated in a recent study using embryonic fibroblasts derived from double knockout mice that lack the expression of both the JNK1 and JNK2 genes (62). It has been suggested that the ability of a cell to die or survive and proliferate may be dictated by a critical balance between the signaling pathways involving the various MAP kinase family members.

In the present study, we have shown that despite the sustained activation of ERK1 and ERK2 by the P2Y1 receptor, a proliferative activity was not apparent. This is analogous to the situation with the somatostatin sst2(a) receptor, which mediates a strong and sustained activity of both ERK1 and ERK2 but that is associated with a concomitant anti-proliferative effect (48). However, activation of the endogenous muscarinic receptors in the astrocytoma cells induced a sustained ERK activation and an associated increase in cell number, suggesting that the proliferative outcome of this cell type is regulated by a complex interplay of transduction cascades. A role for the SAPK family members activated by the P2Y1 receptor in the induction of an apoptotic event was confirmed by showing that the 2-MeSADP-stimulated caspase-3 activity and the associated decrease in cell number was inhibited by the presence of the dominant negative MKK4 mutant. The partial nature of the decrease in both cases could reflect the degree of transient transfection efficiency obtained (~50%). However, it would seem that the p54 and p46 isoforms are much more important for apoptotic function than the p45 SAPK member, as the activity of this latter isoform was relatively unaffected by the MKK4 mutant and was strongly increased by the application of carbachol. The P2Y1 receptor-induced caspase-3 activity, which could be blocked by the selective antagonist, A2P5P, appeared to be unaffected by inhibitors of the Ras-ERK cascade (including the Src inhibitor and a dominant negative Ras mutant). This suggests that there is little cross-talk between the ERK and SAPK cascades activated by the P2Y1 receptor. The role of PI 3-K in regulating the apoptotic function of 2-MeSADP is less clear, as LY 294002 enhanced the basal rate of caspase-3 activity as well as that mediated by the P2Y1 receptor. It is possible that the PI 3-K cascade is having an additional effect on maintaining cell survival that is independent of SAPK inhibition and presumably of its ability to induce ERK phosphorylation. Interestingly, the P2Y1 receptor-mediated apoptotic activity was not sufficient to inhibit cell proliferation induced by 1% serum, despite high concentrations of 2-MeSADP being used to circumvent any problems associated with ligand depletion. It is possible that the transient activation of the SAPK isoforms through P2Y1 receptor activation may be to regulate apoptotic events rather than to induce cell death as shown for the P2X7 receptor that mediates sustained activation of the SAPKs in the presence of serum (32). However, the proliferative activity induced by carbachol was attenuated by the presence of 2-MeSADP, further suggesting that its ability to induce apoptosis is dependent on the net activity of transductional cascades.

In summary, we have demonstrated that the P2Y1 receptor can stimulate the prolonged activation of the ERK cascade leading to the phosphorylation of the transcription factor, Elk-1. This sustained ERK activity is critically dependent on PI 3-K, whereas the transient phase is mediated through Ras with an additional input from both PI 3-K and PKC isoforms. Transient activation of the SAPKs in this system is insufficient for transcription factor phosphorylation but appears to regulate apoptosis through a caspase-3-dependent mechanism. Hence, an identified member of the P2Y receptor family can activate SAPKs (but spares p38 kinase) and can evoke caspase proteolytic activity. This duality suggests that cell proliferation by extracellular nucleotides may be regulated by a critical balance of the activities of those receptor types, which mediate mitogenic or apoptotic processes.

    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ To whom correspondence should be addressed: Glaxo Institute of Applied Pharmacology, Dept. of Pharmacology, University of Cambridge, Tennis Court Rd., Cambridge CB2 1QJ, UK. Tel.: 44-1223-334- 177; Fax: 44-1223-334-178; E-mail: wtem15797@glaxowellcome.co.uk.

Published, JBC Papers in Press, January 25, 2001, DOI 10.1074/jbc.M006617200

    ABBREVIATIONS

The abbreviations used are: 2-MeSATP, 2-methylthio-ATP; 2-MeSADP, 2-methylthio-ADP; MAP, mitogen-activated protein; SAPK, stress-activated protein kinase; ERK, extracellular-signal regulated kinase; MEK, MAP kinase/ERK kinase; PKC, protein kinase C; A2P5P, adenosine-2'-phosphate-5'-phosphate; FITC, fluorescein isothiocyanate; PI 3-K, phosphatidylinositol 3-kinase; TBS, Tris-buffered saline; PBS, phosphate-buffered saline.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Ralevic, V., and Burnstock, G. (1998) Pharmacol. Rev. 50, 413-492[Abstract/Free Full Text]
2. Barnard, E. A., Simon, J., and Webb, T. E. (1997) Mol. Neurobiol. 15, 103-129[Medline] [Order article via Infotrieve]
3. Webb, T. E., Simon, J., Krishek, B. J., Bateson, A. N., Smart, T. G., King, B. F., Burnstock, G., and Barnard, E. A. (1993) FEBS Lett. 324, 219-225[CrossRef][Medline] [Order article via Infotrieve]
4. Tokuyama, Y., Hara, M., Jones, E. M. C., Fan, Z., and Bell, G. I. (1995) Biochem. Biophys. Res. Commun. 211, 211-218[CrossRef][Medline] [Order article via Infotrieve]
5. Ayyanathan, K., Webb, T. E., Sandhu, A. K., Athwal, R. S., Barnard, E. A., and Kunapuli, S. P. (1996) Biochem. Biophys. Res. Commun. 218, 783-788[CrossRef][Medline] [Order article via Infotrieve]
6. Webb, T. E., Simon, J., and Barnard, E. A. (1998) Neuroscience 84, 825-837[CrossRef][Medline] [Order article via Infotrieve]
7. Moore, D., Chambers, J., Waldvogel, H., Faull, R., and Emson, P. (2000) J. Comp. Neurobiol. 421, 374-384[CrossRef][Medline] [Order article via Infotrieve]
8. Valeins, H., Merle, M., and Labouesse, J. (1992) Mol. Pharmacol. 42, 1033-1041[Abstract]
9. Hechler, B., Vigne, P., Leon, C., Breittmayer, J.-P., Gachet, C., and Frelin, C. (1998) Mol. Pharmacol. 53, 727-733[Abstract/Free Full Text]
10. Palmer, R. K., Boyer, J. L., Schachter, J. B., Nicholas, R. A., and Harden, T. K. (1998) Mol. Pharmacol. 54, 1118-1123[Abstract/Free Full Text]
11. Filippov, A., Brown, D. A., and Barnard, E. A. (2000) Br. J. Pharmacol. 129, 1063-1066[Abstract/Free Full Text]
12. Simon, J., Webb, T. E., King, B. F., Burnstock, G., and Barnard, E. A. (1995) Eur. J. Pharmacol. 291, 281-289[CrossRef][Medline] [Order article via Infotrieve]
13. Schachter, J. B., Li, Q., Boyer, J. L., Nicholas, R. A., and Harden, T. K. (1996) Br. J. Pharmacol. 118, 167-173[Abstract]
14. Maurice, D. H., Waldo, G. L., Morris, A. J., Nicholas, R. A., and Harden, T. K. (1993) Biochem. J. 290, 765-770[Medline] [Order article via Infotrieve]
15. Offermanns, S., Toombs, C. F., Hu, Y. H., and Simon, M. I. (1997) Nature 389, 183-186[CrossRef][Medline] [Order article via Infotrieve]
16. Paul, B. Z. S., Daniel, J. L., and Kunapuli, S. P. (1999) J. Biol. Chem. 274, 28293-28300[Abstract/Free Full Text]
17. Widmann, C., Gibson, S., Jarpe, M. B., and Johnson, G. L. (1999) Physiol. Rev. 79, 143-180[Abstract/Free Full Text]
18. Neary, J. T., Kang, Y., Bu, Y., Yu, E., Akong, K., and Peters, C. M. (1999) J. Neuroscience 19, 4211-4220[Abstract/Free Full Text]
19. Lenz, G., Gottfried, C., Luo, Z., Avruch, J., Rodnight, R., Nie, W. J., Kang, Y., and Neary, J. T. (2000) Br. J. Pharmacol. 129, 927-936[Abstract/Free Full Text]
20. Patel, V., Brown, C., Goodwin, A., Wilkie, N., and Boarder, M. R. (1996) Biochem. J. 320, 221-226[Medline] [Order article via Infotrieve]
21. Albert, J. L., Boyle, J. P., Roberts, J. A., Challiss, R. A., Gubby, S. E., and Boarder, M. R. (1997) Br. J. Pharmacol. 122, 935-941[Abstract]
22. Harper, S., Webb, T. E., Charlton, S. J., Ng, L. L., and Boarder, M. R. (1998) Br. J. Pharmacol. 124, 703-710[Abstract]
23. Huwiler, A., and Pfeilschifter, J. (1994) Br. J. Pharmacol. 113, 1455-1463[Abstract]
24. Kyriakis, J. M., and Avruch, J. (1996) J. Biol. Chem. 271, 24313-24316[Free Full Text]
25. Coso, O. A., Teramoto, H., Simonds, W. F., and Gutkind, J. S. (1996) J. Biol. Chem. 271, 3963-3966[Abstract/Free Full Text]
26. Yamauchi, J., Nagao, M., Kaziro, Y., and Itoh, H. (1997) J. Biol. Chem. 272, 27771-27777[Abstract/Free Full Text]
27. Huwiler, A., Wartmann, M., van den Bosch, H., and Pfeilschifter, J. (2000) Br. J. Pharmacol. 129, 612-618[Abstract/Free Full Text]
28. Tu, M.-T., Luo, S.-F., Wang, C.-C., Chien, C.-S., Chiu, C.-T., Lin, C.-C., and Yang, C.-M. (2000) Br. J. Pharmacol. 129, 1481-1489[Abstract/Free Full Text]
29. Harada, H., Chan, C. M., Loesch, A., Unwin, R., and Burnstock, G. (2000) Kidney Int. 57, 949-958[CrossRef][Medline] [Order article via Infotrieve]
30. Zheng, L. M., Zychlinsky, A., Liu, C. C., Ojcius, D. M., and Young, J. D. (1991) J. Cell Biol. 112, 279-288[Abstract]
31. Coutinho-Silva, R., Persechini, P. M., Bisaggio, R. D., Perfettini, J. L., Neto, A. C., Kanellopoulos, J. M., Motta-Ly, I., Dautry-Varsat, A., and Ojcius, D. M. (1999) Am. J. Physiol. 276, C1139-C1147[Abstract/Free Full Text]
32. Humphreys, B. D., Rice, J., Kertesy, S. B., and Dubyak, G. R. (2000) J. Biol. Chem. 275, 26792-26798[Abstract/Free Full Text]
33. Marshall, C. J. (1995) Cell 80, 179-185[Medline] [Order article via Infotrieve]
34. Sellers, L. A., Feniuk, W., Humphrey, P. P. A., and Lauder, H. (1999) J. Biol. Chem. 274, 16423-16430[Abstract/Free Full Text]
35. Dikic, I., Schlessinger, J., and Lax, I. (1994) Curr. Biol. 4, 702-708[Medline] [Order article via Infotrieve]
36. Traverse, S., Seedorf, K., Paterson, H., Marshall, C. J., Cohen, P., and Ullrich, A. (1994) Curr. Biol. 4, 694-701[Medline] [Order article via Infotrieve]
37. Lazarowski, E. R., Homolya, L., Boucher, R. C., and Harden, T. (1997) J. Biol. Chem. 272, 20402-20407[Abstract/Free Full Text]
38. Yamauchi, J., Kaziro, Y., and Itoh, H. (1999) J. Biol. Chem. 274, 1957-1965[Abstract/Free Full Text]
39. Fadok, V. A., Voelker, D. R., Campbell, P. A., Cohen, J. J., Bratton, D. L., and Henson, P. M. (1992) J. Immunol. 148, 2207-2216[Abstract/Free Full Text]
40. Thornberry, N. A., and Lazebnik, Y. (1998) Science 281, 1312-1316[Abstract/Free Full Text]
41. Guizzetti, M., Costa, P., Peters, J., and Costa, L. G. (1996) Eur. J. Pharmacol. 297, 265-273[CrossRef][Medline] [Order article via Infotrieve]
42. Feig, L. A., and Cooper, G. M. (1988) Mol. Cell. Biol. 8, 3235-3243[Medline] [Order article via Infotrieve]
43. Treisman, R. (1994) Curr. Opin. Genet. Dev. 4, 96-101[Medline] [Order article via Infotrieve]
44. Neer, E. J. (1995) Cell 80, 249-257[Medline] [Order article via Infotrieve]
45. Stephens, L. R., Eguinoa, A., Erdjument-Bromage, H., Lui, M., Cooke, F., Coadwell, J., Smrcka, A. S., Thelen, M., Cadwallader, K., Tempst, P., and Hawkins, P. T. (1997) Cell 89, 105-114[Medline] [Order article via Infotrieve]
46. Langhans-Rajasekaran, S. A., Wan, Y., and Huang, X.-Y. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 8601-8605[Abstract]
47. Dikic, I., Tokiwa, G., Lev, S., Courtneidge, S. A., and Schlessinger, J. (1996) Nature 383, 547-550[CrossRef][Medline] [Order article via Infotrieve]
48. Sellers, L. A., Alderton, F., Carruthers, A. M., Schindler, M., and Humphrey, P. P. A. (2000) Mol. Cell. Biol. 20, 5974-5985[Abstract/Free Full Text]
49. Charlesworth, A., and Rozengurt, E. (1997) Oncogene 14, 2323-2329[CrossRef][Medline] [Order article via Infotrieve]
50. Sellers, L. A. (1999) J. Biol. Chem. 274, 24280-24288[Abstract/Free Full Text]
51. Kolch, W., Heidecker, G., Kochs, G., Hummel, R., Vahidi, H., Mischak, H., Finkenzeller, G., Marme, D., and Rapp, U. R. (1993) Nature 364, 249-252[CrossRef][Medline] [Order article via Infotrieve]
52. Sutor, S. L., Vroman, B. T., Armstrong, E. A., Abraham, R. T., and Karnitz, L. M. (1999) J. Biol. Chem. 274, 7002-7010[Abstract/Free Full Text]
53. Wennstrom, S., and Downward, J. (1999) Mol. Cell. Biol. 19, 4279-4288[Abstract/Free Full Text]
54. Takeda, H., Matozaki, T., Takada, T., Noguchi, T., Yamao, T., Tsuda, M., Ochi, F., Fukunaga, K., Inagaki, K., and Kasuga, M. (1999) EMBO J. 18, 386-395[Abstract/Free Full Text]
55. Le Good, J. A., Ziegler, W. H., Parekh, D. B., Alessi, D. R., Cohen, P., and Parker, P. J. (1998) Science 281, 2042-2045[Abstract/Free Full Text]
56. Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T., and Saltiel, A. R. (1995) J. Biol. Chem. 270, 27489-27494[Abstract/Free Full Text]
57. Boyer, J. L., Romero-Avila, T., Schachter, J. B., and Harden, T. K. (1996) Mol. Pharmacol. 50, 1323-1329[Abstract]
58. Paul, A., Torrie, L. J., McLaren, G. J., Kennedy, C., Gould, G. W., and Plevin, R. (2000) J. Biol. Chem. 275, 13243-13249[Abstract/Free Full Text]
59. Gupta, S., Barrett, T., Whitmarsh, A. J., Cavanagh, J., Sluss, H. K., Derijard, B., and Davis, R. J. (1996) EMBO J. 15, 2760-2770[Abstract]
60. Shi, C. S., and Kehrl, J. H. (1997) J. Biol. Chem. 272, 32102-32107[Abstract/Free Full Text]
61. Enslen, H., Tokumitsu, H., Stork, P. J., Davis, R. J., and Soderling, T. R. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 10803-10808[Abstract/Free Full Text]
62. Tournier, C., Hess, P., Yang, D. D., Xu, J., Turner, T. K., Nimnual, A., Bar-Sagi, D., Jones, S. N., Flavell, R. A., and Davis, R. J. (2000) Science 288, 870-874[Abstract/Free Full Text]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.